Nucleotide analog treatment shows promise in hepatitis B-related HCC

Key clinical point: Nucleotide analog therapy (NtA) significantly reduced risk of HCC recurrence and increased overall survival compared to nucleoside analog therapy (NsA) in patients who underwent curative hepatectomy.

Major finding: Compared to NsA therapy, NtA therapy significantly decreased the risk of HCC recurrence (hazard ratio 0.64; P < 0.001) and HCC-related death (HR 0.52; P = 0.001) in patients after surgical resection.

Study details: The data come from a retrospective study of 1,303 adults with hepatitis B-related HCC who received curative hepatectomy at five centers between April 2014 and April 2019.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Qi W et al. Cancer Med. 2021 Oct 13. doi: 10.1002/cam4.4348.

Key clinical point: Nucleotide analog therapy (NtA) significantly reduced risk of HCC recurrence and increased overall survival compared to nucleoside analog therapy (NsA) in patients who underwent curative hepatectomy.

Major finding: Compared to NsA therapy, NtA therapy significantly decreased the risk of HCC recurrence (hazard ratio 0.64; P < 0.001) and HCC-related death (HR 0.52; P = 0.001) in patients after surgical resection.

Study details: The data come from a retrospective study of 1,303 adults with hepatitis B-related HCC who received curative hepatectomy at five centers between April 2014 and April 2019.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Qi W et al. Cancer Med. 2021 Oct 13. doi: 10.1002/cam4.4348.

Key clinical point: Nucleotide analog therapy (NtA) significantly reduced risk of HCC recurrence and increased overall survival compared to nucleoside analog therapy (NsA) in patients who underwent curative hepatectomy.

Major finding: Compared to NsA therapy, NtA therapy significantly decreased the risk of HCC recurrence (hazard ratio 0.64; P < 0.001) and HCC-related death (HR 0.52; P = 0.001) in patients after surgical resection.

Study details: The data come from a retrospective study of 1,303 adults with hepatitis B-related HCC who received curative hepatectomy at five centers between April 2014 and April 2019.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Qi W et al. Cancer Med. 2021 Oct 13. doi: 10.1002/cam4.4348.